Vestal Point Capital, LP
13F filer · CIK 0001974915Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$4.28BU.S. long equity reported on 13F
Positions689 new · 31 closed
Net flow last quarter-$57.8MBuys minus sells
Top 10 positions weight50.3%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202668 positions | |||||
| $345M | 8.06% | 3.11% | +68.5% | Q1 2024 | |
| $317M | 7.40% | 1.85% | +50.4% | Q4 2023 | |
| $313M | 7.32% | 2.99% | +56.6% | Q3 2025 | |
| $236M | 5.51% | 1.02% | +480.0% | Q1 2026 | |
| $203M | 4.74% | 5.46% | +23.1% | Q2 2025 | |
| $195M | 4.56% | 7.76% | +23.9% | Q2 2024 | |
| BTBCAXBicara Therapeutics Inc. | $156M | 3.64% | 7.96% | -3.2% | Q3 2024 |
| $132M | 3.09% | 5.97% | +7.9% | Q2 2025 | |
| $128M | 3.00% | 1.12% | -30.8% | Q4 2025 | |
| $127M | 2.97% | 0.08% | Not reported | Q2 2025 | |
| $121M | 2.82% | 0.72% | +636.8% | Q2 2025 | |
| $113M | 2.65% | 4.04% | +121.4% | Q2 2025 | |
| $111M | 2.60% | 5.40% | +27.7% | Q2 2024 | |
| $102M | 2.38% | 0.97% | +1224.1% | Q1 2026 | |
| $100M | 2.34% | 0.61% | Not reported | Q4 2023 | |
| $85.3M | 1.99% | Not reported | +350.0% | Q4 2023 | |
| $85.3M | 1.99% | 0.16% | +42.9% | Q4 2023 | |
| $84.3M | 1.97% | 0.21% | -81.1% | Q4 2023 | |
| $83M | 1.94% | 3.25% | +18.2% | Q4 2025 | |
| $75M | 1.75% | 2.04% | -15.6% | Q2 2024 | |
| $69.8M | 1.63% | 4.91% | +250.9% | Q1 2026 | |
| $67.2M | 1.57% | 0.63% | +39.2% | Q4 2023 | |
| $66.1M | 1.54% | 2.43% | +425.0% | Q3 2024 | |
| $62.6M | 1.46% | 4.61% | Not reported | Q4 2023 | |
| $57.8M | 1.35% | 2.18% | +43.1% | Q1 2026 | |
| $57.2M | 1.34% | 3.50% | -34.9% | Q4 2025 | |
| $54.6M | 1.28% | 0.71% | -56.8% | Q3 2025 | |
| $46.1M | 1.08% | 0.04% | -20.0% | Q2 2024 | |
| $43.1M | 1.01% | 1.35% | +160.5% | Q4 2023 | |
| $42.3M | 0.99% | 0.72% | +9.4% | Q4 2023 | |
| $38.3M | 0.89% | 7.14% | +10.7% | Q1 2026 | |
| $34.9M | 0.82% | 0.28% | +106.6% | Q3 2024 | |
| $33.6M | 0.78% | 0.10% | -37.5% | Q2 2025 | |
| $32.7M | 0.77% | 6.00% | +248.0% | Q3 2025 | |
| $30.4M | 0.71% | 1.52% | -49.2% | Q3 2025 | |
| $29.3M | 0.69% | 5.87% | +8.7% | Q4 2025 | |
| $28.8M | 0.67% | 0.10% | +80.0% | Q1 2025 | |
| $26.7M | 0.62% | 0.11% | Not reported | Q4 2023 | |
| $26.5M | 0.62% | 0.58% | -25.6% | Q1 2024 | |
| $25.1M | 0.59% | 3.56% | -27.7% | Q2 2025 | |
| $24.9M | 0.58% | 0.04% | Not reported | Q4 2023 | |
| $21.6M | 0.50% | 2.05% | -56.8% | Q4 2023 | |
| $20.7M | 0.48% | 2.24% | -62.0% | Q1 2024 | |
| $20.4M | 0.48% | 2.86% | New | Q2 2026 | |
| $20.1M | 0.47% | 5.49% | -3.5% | Q1 2024 | |
| $16.8M | 0.39% | 1.32% | +4.6% | Q2 2024 | |
| $15M | 0.35% | 0.93% | -4.2% | Q1 2026 | |
| $14.9M | 0.35% | 2.00% | +0.5% | Q1 2026 | |
| $14.6M | 0.34% | 2.21% | +29.6% | Q4 2025 | |
| $14.3M | 0.33% | 1.47% | New | Q2 2026 | |
| Q1 2026Reported May 15, 202690 positions | |||||
| $231M | 6.46% | 1.19% | +705.1% | Q4 2023 | |
| $202M | 5.65% | 1.85% | +19.2% | Q1 2024 | |
| $167M | 4.67% | 1.91% | -21.1% | Q3 2025 | |
| $165M | 4.60% | 1.24% | Not reported | Q4 2023 | |
| $143M | 3.99% | 1.62% | +152.8% | Q4 2025 | |
| $127M | 3.56% | 5.34% | -15.1% | Q2 2025 | |
| $109M | 3.05% | 1.64% | +1014.5% | Q3 2025 | |
| BTBCAXBicara Therapeutics Inc. | $108M | 3.02% | 8.28% | +51.8% | Q3 2024 |
| $101M | 2.82% | 6.29% | +38.6% | Q2 2024 | |
| ATAPGEApogee Therapeutics, Inc. | $92.6M | 2.59% | 1.47% | +100.0% | Q3 2024 |
| $85.8M | 2.40% | 0.61% | +114.3% | Q4 2023 | |
| $83.4M | 2.33% | 5.44% | +373.0% | Q4 2025 | |
| $80.5M | 2.25% | 6.27% | +30.9% | Q2 2025 | |
| $72.5M | 2.03% | 2.42% | +3233.3% | Q2 2024 | |
| $67.5M | 1.89% | 0.11% | Not reported | Q4 2023 | |
| $66.9M | 1.87% | 2.77% | +212.2% | Q4 2025 | |
| $65.1M | 1.82% | 1.11% | +89.2% | Q1 2025 | |
| $60.8M | 1.70% | 4.61% | +0.8% | Q4 2023 | |
| $60.7M | 1.70% | 0.05% | +300.0% | Q2 2024 | |
| $60.3M | 1.69% | 0.16% | -27.6% | Q2 2025 | |
| $59.3M | 1.66% | 4.27% | +365.0% | Q2 2024 | |
| $55M | 1.54% | 2.14% | +148.8% | Q4 2024 | |
| TPTERNTerns Pharmaceuticals, Inc. | $52.7M | 1.47% | 0.87% | -77.8% | Q4 2025 |
| $52.6M | 1.47% | 0.45% | -52.1% | Q4 2023 | |
| $50.2M | 1.40% | 0.05% | New | Q1 2026 | |
| NNUVLNuvalent, Inc. | $49.4M | 1.38% | 15.39% | +947.2% | Q4 2023 |
| $47.4M | 1.32% | 0.72% | Not reported | Q1 2025 | |
| $46.4M | 1.30% | 5.89% | -16.9% | Q1 2024 | |
| $44.9M | 1.26% | 3.00% | +29.4% | Q3 2025 | |
| $44.8M | 1.25% | 1.83% | -4.8% | Q2 2025 | |
| $44.5M | 1.24% | 0.18% | New | Q1 2026 | |
| $38.8M | 1.09% | 1.84% | +5.1% | Q4 2024 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $37.2M | 1.04% | 3.61% | -2.1% | Q1 2024 |
| $37.2M | 1.04% | 0.66% | +6.7% | Q4 2023 | |
| $36M | 1.01% | 5.08% | -14.0% | Q4 2023 | |
| $35.9M | 1.00% | 6.45% | New | Q1 2026 | |
| $34.4M | 0.96% | 0.51% | New | Q1 2026 | |
| $34M | 0.95% | 1.12% | +281.4% | Q2 2024 | |
| $30.9M | 0.86% | 0.04% | Not reported | Q4 2023 | |
| $29.8M | 0.83% | 0.10% | New | Q1 2026 | |
| $29.7M | 0.83% | 0.79% | Not reported | Q1 2024 | |
| $27.8M | 0.78% | 1.87% | Not reported | Q2 2024 | |
| $27.6M | 0.77% | 5.44% | Not reported | Q4 2025 | |
| $25.8M | 0.72% | 1.69% | New | Q1 2026 | |
| $25.7M | 0.72% | 6.04% | Not reported | Q1 2024 | |
| STSLNOSoleno Therapeutics Inc | $24.4M | 0.68% | 1.41% | Not reported | Q4 2023 |
| $22.2M | 0.62% | 4.96% | +268.6% | Q2 2025 | |
| $20.5M | 0.57% | 1.40% | New | Q1 2026 | |
| $19.8M | 0.55% | 0.24% | Not reported | Q4 2023 | |
| $19.7M | 0.55% | Not reported | Not reported | Q4 2023 | |
| Q4 2025Reported Feb 17, 202675 positions | |||||
| $256M | 8.71% | 2.42% | +90.0% | Q3 2025 | |
| AACLXArcellx, Inc. | $191M | 6.48% | 5.05% | +134.0% | Q4 2023 |
| TPTERNTerns Pharmaceuticals, Inc. | $182M | 6.18% | 4.01% | New | Q4 2025 |
| $178M | 6.06% | 1.56% | +261.5% | Q1 2024 | |
| $111M | 3.78% | 0.95% | +2.0% | Q4 2023 | |
| $89M | 3.02% | 4.61% | +35.0% | Q2 2024 | |
| $87.1M | 2.96% | 0.23% | +0.5% | Q2 2025 | |
| $84.6M | 2.88% | 0.33% | +96.2% | Q3 2025 | |
| $81.6M | 2.77% | 0.03% | Not reported | Q4 2023 | |
| $75.6M | 2.57% | 4.82% | +150.0% | Q2 2025 | |
| $75.2M | 2.56% | 0.03% | +140.0% | Q2 2025 | |
| $64.3M | 2.19% | 4.57% | -3.5% | Q4 2023 | |
| $63.8M | 2.17% | 4.52% | Not reported | Q4 2024 | |
| BTBCAXBicara Therapeutics Inc. | $60.2M | 2.05% | 6.32% | -29.9% | Q3 2024 |
| $59.8M | 2.03% | 0.66% | New | Q4 2025 | |
| $59M | 2.01% | 6.44% | +230.2% | Q2 2025 | |
| $58.4M | 1.98% | 1.94% | +47.0% | Q2 2025 | |
| $49.3M | 1.68% | 0.47% | -42.0% | Q4 2023 | |
| DODAWNDay One Biopharmaceuticals, Inc. | $48.5M | 1.65% | 5.05% | +94.4% | Q2 2024 |
| $44.4M | 1.51% | 6.13% | +37.7% | Q1 2024 | |
| $44.2M | 1.50% | 7.78% | +161.6% | Q1 2024 | |
| ATAPGEApogee Therapeutics, Inc. | $41.5M | 1.41% | 0.80% | +29.4% | Q3 2024 |
| $41.3M | 1.40% | 2.03% | New | Q4 2025 | |
| $38.4M | 1.30% | 0.41% | +40.0% | Q2 2024 | |
| $37.3M | 1.27% | 0.28% | -70.8% | Q4 2023 | |
| $33.7M | 1.14% | 2.32% | +16.8% | Q3 2025 | |
| $32.8M | 1.12% | 7.36% | +95.5% | Q4 2023 | |
| $31.6M | 1.08% | 1.75% | -3.3% | Q4 2024 | |
| $30.8M | 1.05% | 0.65% | -53.3% | Q1 2025 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $30.5M | 1.04% | 3.71% | +152.0% | Q1 2024 |
| $27.9M | 0.95% | 0.86% | -27.6% | Q4 2024 | |
| $26.9M | 0.91% | 0.75% | -45.5% | Q4 2023 | |
| $24M | 0.81% | 0.56% | +111.8% | Q2 2025 | |
| $23.5M | 0.80% | 0.15% | -53.2% | Q4 2023 | |
| $22.8M | 0.77% | 1.16% | -51.0% | Q2 2024 | |
| $20.3M | 0.69% | 1.15% | New | Q4 2025 | |
| $19.5M | 0.66% | 1.33% | New | Q4 2025 | |
| $18.3M | 0.62% | 1.35% | Not reported | Q2 2025 | |
| $17.8M | 0.60% | 5.44% | New | Q4 2025 | |
| $17.6M | 0.60% | 1.06% | New | Q4 2025 | |
| $15.5M | 0.53% | 0.13% | Not reported | Q3 2024 | |
| $14.9M | 0.51% | 1.77% | -34.3% | Q1 2024 | |
| $13.6M | 0.46% | 0.15% | -79.3% | Q3 2025 | |
| $13.5M | 0.46% | 0.08% | Not reported | Q2 2025 | |
| $13.5M | 0.46% | 0.01% | Not reported | Q2 2024 | |
| $12.2M | 0.41% | 1.18% | -3.1% | Q2 2024 | |
| $10.7M | 0.37% | 1.43% | Not reported | Q4 2023 | |
| $9.68M | 0.33% | 0.79% | -60.0% | Q2 2024 | |
| $9.53M | 0.32% | 1.58% | +185.1% | Q4 2024 | |
| $8.85M | 0.30% | 0.56% | +155.9% | Q1 2024 | |
| Q3 2025Reported Nov 14, 202580 positions | |||||
| $119M | 5.39% | 0.99% | +200.0% | Q4 2023 | |
| AACLXArcellx, Inc. | $103M | 4.63% | 2.16% | -54.6% | Q4 2023 |
| NNUVLNuvalent, Inc. | $95.1M | 4.30% | 35.15% | +2.3% | Q4 2023 |
| $84.9M | 3.83% | 1.58% | New | Q3 2025 | |
| $82M | 3.70% | 0.22% | +109.5% | Q2 2025 | |
| BTBCAXBicara Therapeutics Inc. | $80.5M | 3.64% | 9.34% | +2.0% | Q3 2024 |
| ATFOLDAmicus Therapeutics, Inc. | $76.8M | 3.47% | 3.16% | -18.1% | Q4 2024 |
| $71.6M | 3.23% | 0.93% | +150.0% | Q4 2023 | |
| $70.3M | 3.18% | 0.67% | +115.0% | Q4 2024 | |
| $65.9M | 2.98% | 0.82% | -58.3% | Q4 2023 | |
| $60.8M | 2.75% | 0.11% | +1200.0% | Q3 2024 | |
| $55.9M | 2.52% | 1.51% | Not reported | Q1 2025 | |
| $54.1M | 2.44% | 5.22% | +1.6% | Q4 2023 | |
| $53.5M | 2.41% | 0.71% | New | Q3 2025 | |
| $46.4M | 2.10% | 2.75% | -63.1% | Q4 2023 | |
| $45M | 2.03% | 0.43% | +66.0% | Q1 2024 | |
| $44.2M | 1.99% | 1.43% | -45.0% | Q4 2023 | |
| $43.7M | 1.98% | 0.17% | New | Q3 2025 | |
| $39.8M | 1.80% | 0.61% | -75.6% | Q4 2023 | |
| $38.5M | 1.74% | 0.19% | Not reported | Q4 2023 | |
| CTCDTXCidara Therapeutics, Inc. | $38.3M | 1.73% | 1.36% | -20.0% | Q1 2025 |
| ATATXSAstria Therapeutics, Inc. | $36.1M | 1.63% | 8.78% | +9.6% | Q1 2024 |
| $35.1M | 1.59% | 1.95% | +281.4% | Q2 2024 | |
| $33.9M | 1.53% | 4.55% | -8.7% | Q4 2024 | |
| $33.5M | 1.51% | 0.01% | +42.9% | Q2 2025 | |
| $33M | 1.49% | 1.43% | +257.1% | Q2 2025 | |
| $32.1M | 1.45% | 4.52% | +73.8% | Q2 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $31.2M | 1.41% | 0.79% | -50.0% | Q4 2023 |
| $31.2M | 1.41% | 1.81% | -31.1% | Q4 2024 | |
| $30.1M | 1.36% | 2.35% | +53.5% | Q2 2024 | |
| $29.7M | 1.34% | 0.02% | +200.0% | Q1 2025 | |
| $29.4M | 1.33% | 0.33% | -47.5% | Q4 2023 | |
| $28.2M | 1.27% | 1.99% | New | Q3 2025 | |
| $23.7M | 1.07% | 1.96% | +364.0% | Q2 2025 | |
| $23.6M | 1.07% | 2.70% | -27.6% | Q1 2024 | |
| $23.1M | 1.04% | 0.98% | New | Q3 2025 | |
| $22.6M | 1.02% | 0.78% | Not reported | Q1 2024 | |
| $22.1M | 1.00% | 1.19% | -75.5% | Q4 2024 | |
| $21.6M | 0.97% | 5.92% | +0.7% | Q1 2024 | |
| $21M | 0.95% | 9.75% | -0.9% | Q2 2024 | |
| DODAWNDay One Biopharmaceuticals, Inc. | $18.9M | 0.85% | 2.61% | -10.8% | Q2 2024 |
| $18.4M | 0.83% | 3.82% | +97.7% | Q4 2023 | |
| $18.2M | 0.82% | 0.30% | Not reported | Q2 2024 | |
| $18M | 0.81% | 2.01% | +83.3% | Q2 2025 | |
| ATAPGEApogee Therapeutics, Inc. | $16.9M | 0.76% | 0.72% | Not reported | Q3 2024 |
| $14.3M | 0.65% | 2.32% | -63.6% | Q2 2024 | |
| $14.3M | 0.65% | 0.29% | -12.0% | Q3 2024 | |
| $14.1M | 0.63% | 0.03% | Not reported | Q4 2023 | |
| $13.1M | 0.59% | 0.36% | -93.9% | Q4 2023 | |
| $11.9M | 0.54% | 1.36% | +9.1% | Q2 2025 | |
Premium opens every quarter this fund has filed